Monitoring quality of life in patients with haematological malignancies
Clinical Previous     Next

Monitoring quality of life in patients with haematological malignancies

Lesley Grimmer Clinical nurse specialist in haematology, Department of clinical haematology at the Queen Elizabeth Hospital, King’s Lynn, Norfolk
Claire Atterbury Clinical nurse specialist in haematology and transfusion, Department of haematology at the Queen Elizabeth Hospital, King’s Lynn, Norfolk
Jane Keidan Consultant haematologist, Queen Elizabeth Hospital, King’s Lynn, Norfolk

Intensive treatment for haematological malignancies can have an enormous effect on the patient’s quality of life (QoL) and may lead to psychosocial problems during and after treatment. This paper describes a method of monitoring QoL in patients receiving intensive chemotherapy to enable prompt medical, social and/or psychological intervention where necessary. A structured approach to psychosocial assessment revealed that the HAD scores of Hodgkin’s patients were significantly higher compared with cases of other haematological malignancies. Hodgkin’s disease patients are now automatically assessed formally by a clinical psychologist at diagnosis.

Cancer Nursing Practice. 3, 7,24-30. doi: 10.7748/cnp2004.09.3.7.24.c134

You need a subscription to read the full article